Apollo Clinic To Offer DNA Health Tests

Apollo Clinic joins hands with Mapmygenome to launch genomics-based healthcare at its centres in India.

Genomepatri (the name stands for ‘health horoscope’) is a master health test with over 100 reports on lifestyle disease, physiological traits, drug response, and carrier status. A flagship product from Mapmygenome, it is the most comprehensive genetic assessment available for preventive screening. Genomepatri Lite is a specialized product with a focus on cardiology and oncology. It comes with 50 reports on heart health, metabolic traits, cancer risk (15 different types of cancer), and drug response (15 commonly prescribed statins, beta-blockers, blood thinners, and anti-diabetic agents). Genomepatri and Genomepatri Lite include genetic risk assessment of health risks which affect COVID severity and immunity, as well. With a database of 10000+ samples, Genomepatri Heritage is the first DNA ancestry test that offers ethnicity mapping for the Indian population.

The tests are powered by Mapmygenome, a pioneer in Indian genomics. All products are backed by 20 years of genomic research and validation in thousands of samples, including Indians. The tests can be done on the buccal swab (noninvasive) or blood samples of the patients. 

These products enable early intervention, risk mitigation, and better prevention, by identifying health risks and providing customized action plans. “The power of genomics increases much fold when it is utilized by doctors for enhanced patient care. We are glad this is happening now. This unique partnership comes at a crucial time when better prevention and personalized medicine is the need of the hour,” said AnuAcharya, CEO, Mapmygenome.

Speaking about this collaboration, Anand Wasker, COO, Apollo Clinic, said, “With Mapmygenome onboard, Apollo Clinic has added an entirely new dimension to preventive healthcare. Our partnership will enable us to improve the quality of life for our patients even before they face any issues.”